|
1
|
Ren Y, Shi T, Jiang R, Yin S, Wang P and
Zang R: Multiple cycles of neoadjuvant chemotherapy associated with
poor survival in bulky stage IIIC and IV ovarian cancer. Int J
Gynecol Cancer. 25:1398–1404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Falandry C, Weber B, Savoye AM, Tinquaut
F, Tredan O, Sevin E, Stefani L, Savinelli F, Atlassi M, Salvat J,
et al: Development of a geriatric vulnerability score in elderly
patients with advanced ovarian cancer treated with first-line
carboplatin: A GINECO prospective trial. Ann Oncol. 24:2808–2813.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fisher M and Gore M: Cost-effectiveness of
trabectedin plus pegylated liposomal doxorubicin for the treatment
of women with relapsed platinum-sensitive ovarian cancer in the UK:
Analysis based on the final survival data of the OVA-301 trial.
Value Health. 16:507–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kehoe S, Hook J, Nankivell M, Jayson GC,
Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M,
et al: Primary chemotherapy versus primary surgery for newly
diagnosed advanced ovarian cancer (CHORUS): An open-label,
randomised, controlled, non-inferiority trial. Lancet. 386:249–257.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyake T, Kumasawa K, Sato N, Takiuchi T,
Nakamura H and Kimura T: Soluble VEGF receptor 1 (sFLT1) induces
non-apoptotic death in ovarian and colorectal cancer cells. Sci
Rep. 6:248532016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Camerin GR, Brito AB, Vassallo J, Derchain
SF and Lima CS: VEGF gene polymorphisms and outcome of epithelial
ovarian cancer patients. Future Oncol. 13:409–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim BR, Yoon K, Byun HJ, Seo SH, Lee SH
and Rho SB: The anti-tumor activator sMEK1 and paclitaxel
additively decrease expression of HIF-1α and VEGF via
mTORC1-S6K/4E-BP-dependent signaling pathways. Oncotarget.
5:6540–6551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ganta S, Singh A, Patel NR, Cacaccio J,
Rawal YH, Davis BJ, Amiji MM and Coleman TP: Development of
EGFR-targeted nanoemulsion for imaging and novel platinum therapy
of ovarian cancer. Pharm Res. 31:2490–2502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ranjbar R, Nejatollahi F, Ahmadi Nedaei
AS, Hafezi H and Safaie A: Expression of vascular endothelial
growth factor (VEGF) and epidermal growth factor receptor (EGFR) in
patients with serous ovarian carcinoma and their clinical
significance. Iran J Cancer Prev. 8:e34282015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kodigepalli KM, Dutta PS, Bauckman KA and
Nanjundan M: SnoN/SkiL expression is modulated via arsenic
trioxide-induced activation of the PI3K/AKT pathway in ovarian
cancer cells. FEBS Lett. 587:5–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Glaysher S, Bolton LM, Johnson P, Atkey N,
Dyson M, Torrance C and Cree IA: Targeting EGFR and PI3K pathways
in ovarian cancer. Br J Cancer. 109:1786–1794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu M, Chen X, Lou J, Zhang S, Zhang X,
Huang L, Sun R, Huang P, Wang F and Pan S: TGF-β1 contributes to
CD8+ Treg induction through p38 MAPK signaling in ovarian cancer
microenvironment. Oncotarget,. 7:44534–44544. 2016.
|
|
13
|
Wang F, Chang Z, Fan Q and Wang L:
Epigallocatechin-3-gallate inhibits the proliferation and migration
of human ovarian carcinoma cells by modulating p38 kinase and
matrix metalloproteinase-2. Mol Med Rep. 9:1085–1089. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu M, Xiao L, Hu J, Deng S and Xu Y:
Targeting of p38 mitogen-activated protein kinases to early growth
response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian
carcinoma cells. J Huazhong Univ Sci Technolog Med Sci. 28:451–455.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tong Q, Qing Y, Wu Y, Hu X, Jiang L and Wu
X: Dioscin inhibits colon tumor growth and tumor angiogenesis
through regulating VEGFR2 and AKT/MAPK signaling pathways. Toxicol
Appl Pharmacol. 281:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi M, Yin L, Xu L, Tao X, Qi Y, Han X,
Wang C, Xu Y, Sun H, Liu K and Peng J: Dioscin alleviates
lipopolysaccharide-induced inflammatory kidney injury via the
microRNA let-7i/TLR4/MyD88 signaling pathway. Pharmacol Res.
111:509–522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, He QY and Chiu JF: Dioscin induced
activation of p38 MAPK and JNK via mitochondrial pathway in HL-60
cell line. Eur J Pharmacol. 735:52–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith HO, Moon J, Wilczynski SP, Tiersten
AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY and
Markman M: Southwest oncology group trial S9912: Intraperitoneal
cisplatin and paclitaxel plus intravenous paclitaxel and pegylated
liposomal doxorubicin as primary chemotherapy of small-volume
residual stage III ovarian cancer. Gynecol Oncol. 114:206–209.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Noonan AM, Bunch KP, Chen JQ, Herrmann MA,
Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, et
al: Pharmacodynamic markers and clinical results from the phase 2
study of the SMAC mimetic birinapant in women with relapsed
platinum-resistant or -refractory epithelial ovarian cancer.
Cancer. 122:588–597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adham SA, Sher I and Coomber BL: Molecular
blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab
Invest. 90:709–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu W, Chen H, Yel F, Wang F and Xie X:
VEGF induces phosphorylation of STAT3 through binding VEGFR2 in
ovarian carcinoma cells in vitro. Eur J Gynaecol Oncol. 27:363–369.
2006.PubMed/NCBI
|
|
22
|
Barua A, Yellapa A, Bahr JM, Machado SA,
Bitterman P, Basu S, Sharma S and Abramowicz JS: VEGFR2-targeted
ultrasound imaging agent enhances the detection of ovarian tumors
at early stage in laying hens, a preclinical model of spontaneous
ovarian cancer. Ultrason Imaging. 37:224–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ye J, Chen W, Wu ZY, Zhang JH, Fei H,
Zhang LW, Wang YH, Chen YP and Yang XM: Upregulated CTHRC1 promotes
human epithelial ovarian cancer invasion through activating EGFR
signaling. Oncol Rep. 36:3588–3596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baron AT, Wilken JA, Haggstrom DE,
Goodrich ST and Maihle NJ: Clinical implementation of soluble EGFR
(sEGFR) as a theragnostic serum biomarker of breast, lung and
ovarian cancer. IDrugs. 12:302–308. 2009.PubMed/NCBI
|
|
25
|
Zhao J, Klausen C, Qiu X, Cheng JC, Chang
HM and Leung PC: Betacellulin induces slug-mediated down-regulation
of E-cadherin and cell migration in ovarian cancer cells.
Oncotarget. 7:28881–28890. 2016.PubMed/NCBI
|
|
26
|
Hsieh MJ, Tsai TL, Hsieh YS, Wang CJ and
Chiou HL: Dioscin-induced autophagy mitigates cell apoptosis
through modulation of PI3K/Akt and ERK and JNK signaling pathways
in human lung cancer cell lines. Arch Toxicol. 87:1927–1937. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malm SW, Hanke NT, Gill A, Carbajal L and
Baker AF: The anti-tumor efficacy of 2-deoxyglucose and D-allose
are enhanced with p38 inhibition in pancreatic and ovarian cell
lines. J Exp Clin Cancer Res. 34:312015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu W, Gu J, Ren Q, Shi Y, Xia Q and Wang
J, Wang S, Wang Y and Wang J: NFATC1 promotes cell growth and
tumorigenesis in ovarian cancer up-regulating c-Myc through
ERK1/2/p38 MAPK signal pathway. Tumour Biol. 37:4493–4500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Watson JL, Greenshields A, Hill R, Hilchie
A, Lee PW, Giacomantonio CA and Hoskin DW: Curcumin-induced
apoptosis in ovarian carcinoma cells is p53-independent and
involves p38 mitogen-activated protein kinase activation and
downregulation of Bcl-2 and survivin expression and Akt signaling.
Mol Carcinog. 49:13–24. 2010.PubMed/NCBI
|
|
30
|
Zhang B, Wang X, Cai F, Chen W, Loesch U
and Zhong XY: Antitumor properties of salinomycin on
cisplatin-resistant human ovarian cancer cells in vitro and in
vivo: Involvement of p38 MAPK activation. Oncol Rep. 29:1371–1378.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Buldak RJ, Polaniak R, Buldak L,
Mielanczyk L, Kukla M, Skonieczna M, Dulawa-Buldak A, Matysiak N
and Zwirska-Korczala K: Exogenous administration of visfatin
affects cytokine secretion and increases oxidative stress in human
malignant melanoma Me45 cells. J Physiol Pharmacol. 64:377–385.
2013.PubMed/NCBI
|
